107 related articles for article (PubMed ID: 28407032)
1. Toll-like receptor 5 agonist CBLB502 induces radioprotective effects in vitro.
Shi T; Li L; Zhou G; Wang C; Chen X; Zhang R; Xu J; Lu X; Jiang H; Chen J
Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):487-495. PubMed ID: 28407032
[TBL] [Abstract][Full Text] [Related]
2. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models.
Burdelya LG; Krivokrysenko VI; Tallant TC; Strom E; Gleiberman AS; Gupta D; Kurnasov OV; Fort FL; Osterman AL; Didonato JA; Feinstein E; Gudkov AV
Science; 2008 Apr; 320(5873):226-30. PubMed ID: 18403709
[TBL] [Abstract][Full Text] [Related]
3. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist.
Burdelya LG; Brackett CM; Kojouharov B; Gitlin II; Leonova KI; Gleiberman AS; Aygun-Sunar S; Veith J; Johnson C; Haderski GJ; Stanhope-Baker P; Allamaneni S; Skitzki J; Zeng M; Martsen E; Medvedev A; Scheblyakov D; Artemicheva NM; Logunov DY; Gintsburg AL; Naroditsky BS; Makarov SS; Gudkov AV
Proc Natl Acad Sci U S A; 2013 May; 110(20):E1857-66. PubMed ID: 23630282
[TBL] [Abstract][Full Text] [Related]
4. NLRC4 Mutation in flagellin-derived peptide CBLB502 ligand-binding domain reduces the inflammatory response but not radioprotective activity.
Lai L; Yang G; Yao X; Wang L; Zhan Y; Yu M; Yin R; Li C; Yang X; Ge C
J Radiat Res; 2019 Nov; 60(6):780-785. PubMed ID: 31599956
[TBL] [Abstract][Full Text] [Related]
5. Radioprotective effect of newly synthesized toll-like receptor 5 agonist, KMRC011, in mice exposed to total-body irradiation.
Kim JY; Park JH; Seo SM; Park JI; Jeon HY; Lee HK; Yoo RJ; Lee YJ; Woo SK; Lee WJ; Choi CM; Choi YK
J Radiat Res; 2019 Jul; 60(4):432-441. PubMed ID: 31165150
[TBL] [Abstract][Full Text] [Related]
6. CBLB502, an agonist of Toll-like receptor 5, has antioxidant and scavenging free radicals activities in vitro.
Li W; Ge C; Yang L; Wang R; Lu Y; Gao Y; Li Z; Wu Y; Zheng X; Wang Z; Zhang C
Int J Biol Macromol; 2016 Jan; 82():97-103. PubMed ID: 26476243
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy.
Burdelya LG; Gleiberman AS; Toshkov I; Aygun-Sunar S; Bapardekar M; Manderscheid-Kern P; Bellnier D; Krivokrysenko VI; Feinstein E; Gudkov AV
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):228-34. PubMed ID: 22000579
[TBL] [Abstract][Full Text] [Related]
8. CBLB502, a Toll-like receptor 5 agonist, offers protection against radiation-induced male reproductive system damage in mice.
Bai H; Sun F; Yang G; Wang L; Zhang Q; Zhang Q; Zhan Y; Chen J; Yu M; Li C; Yin R; Yang X; Ge C
Biol Reprod; 2019 Jan; 100(1):281-291. PubMed ID: 30084935
[TBL] [Abstract][Full Text] [Related]
9. A flagellin-derived toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity.
Leigh ND; Bian G; Ding X; Liu H; Aygun-Sunar S; Burdelya LG; Gudkov AV; Cao X
PLoS One; 2014; 9(1):e85587. PubMed ID: 24454895
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor 5 agonism protects mice from radiation pneumonitis and pulmonary fibrosis.
Wang ZD; Qiao YL; Tian XF; Zhang XQ; Zhou SX; Liu HX; Chen Y
Asian Pac J Cancer Prev; 2012; 13(9):4763-7. PubMed ID: 23167416
[TBL] [Abstract][Full Text] [Related]
11. A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease.
Ding X; Bian G; Leigh ND; Qiu J; McCarthy PL; Liu H; Aygun-Sunar S; Burdelya LG; Gudkov AV; Cao X
J Immunol; 2012 Nov; 189(10):4719-27. PubMed ID: 23045613
[TBL] [Abstract][Full Text] [Related]
12. Anti-radiation damage effect of polyethylenimine as a toll-like receptor 5 targeted agonist.
Hu Z; Xing Y; Qian Y; Chen X; Tu J; Ren L; Wang K; Chen Z
J Radiat Res; 2013 Mar; 54(2):243-50. PubMed ID: 23104900
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor 5 signaling restrains T-cell/natural killer T-cell activation and protects against concanavalin A-induced hepatic injury.
Wang L; Zhang W; Ge CH; Yin RH; Xiao Y; Zhan YQ; Yu M; Li CY; Ge ZQ; Yang XM
Hepatology; 2017 Jun; 65(6):2059-2073. PubMed ID: 28273362
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of the TLR5 agonist CBLB502 and its downstream effector IL-22 against liver injury.
Melin N; Sánchez-Taltavull D; Fahrner R; Keogh A; Dosch M; Büchi I; Zimmer Y; Medová M; Beldi G; Aebersold DM; Candinas D; Stroka D
Cell Death Dis; 2021 Apr; 12(4):366. PubMed ID: 33824326
[TBL] [Abstract][Full Text] [Related]
15. Identification of granulocyte colony-stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure.
Krivokrysenko VI; Shakhov AN; Singh VK; Bone F; Kononov Y; Shyshynova I; Cheney A; Maitra RK; Purmal A; Whitnall MH; Gudkov AV; Feinstein E
J Pharmacol Exp Ther; 2012 Nov; 343(2):497-508. PubMed ID: 22837010
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptors and radiation protection.
Liu Z; Lei X; Li X; Cai JM; Gao F; Yang YY
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(1):31-39. PubMed ID: 29364499
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor 5 agonist inhibition of growth of A549 lung cancer cells in vivo in a Myd88 dependent manner.
Zhou SX; Li FS; Qiao YL; Zhang XQ; Wang ZD
Asian Pac J Cancer Prev; 2012; 13(6):2807-12. PubMed ID: 22938463
[TBL] [Abstract][Full Text] [Related]
18. A TLR5 agonist inhibits acute renal ischemic failure.
Fukuzawa N; Petro M; Baldwin WM; Gudkov AV; Fairchild RL
J Immunol; 2011 Oct; 187(7):3831-9. PubMed ID: 21890657
[TBL] [Abstract][Full Text] [Related]
19. Podophyllum hexandrum fraction (REC-2006) shows higher radioprotective efficacy in the p53-carrying hepatoma cell line: a role of cell cycle regulatory proteins.
Singh PK; Kumar R; Sharma A; Arora R; Chawla R; Jain SK; Sharma RK
Integr Cancer Ther; 2009 Sep; 8(3):261-72. PubMed ID: 19815596
[TBL] [Abstract][Full Text] [Related]
20. A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications.
Mett V; Kurnasov OV; Bespalov IA; Molodtsov I; Brackett CM; Burdelya LG; Purmal AA; Gleiberman AS; Toshkov IA; Burkhart CA; Kogan YN; Andrianova EL; Gudkov AV; Osterman AL
Commun Biol; 2021 Apr; 4(1):466. PubMed ID: 33846531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
